Genetic androgenetic alopecia (male pattern baldness), driven primarily by DHT sensitivity at the follicle, won't respond to B12 alone that requires targeted intervention like Maximus' hair regrowth protocols, which address DHT blocking and follicle stimulation directly
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
*Correspondence: Xianxiang Tian, [email protected]
Methylation values were obtained using the SeSAMe-based harmonization workflow from GDC
We also know that high levels of human growth hormone over a long period can produce irreversible acromegaly, the complications of which include arthritis, sleep apnoea, diabetes, high blood pressure, heart disease and often premature death